Lyrica (pregabalin) is a Schedule V controlled substance because it produced unusually high rates of euphoria in clinical trials before it was ever approved. Neurontin (gabapentin) did not trigger the same signals during its approval process, so it was never federally scheduled. The two drugs work on the same target in the brain, but pregabalin is faster-acting, more potent, and absorbed more predictably, all of which make it more likely to produce a “high.”
How the Two Drugs Differ in the Body
Pregabalin and gabapentin both bind to the same part of voltage-gated calcium channels in the nervous system, reducing the release of excitatory signals. This is how they ease nerve pain, calm seizure activity, and reduce anxiety. But pregabalin is 2 to 10 times more potent at that binding site. A typical conversion when switching patients illustrates the gap: 900 mg per day of gabapentin corresponds to just 150 mg per day of pregabalin.
The bigger difference is how each drug gets absorbed. Gabapentin relies on a single transport system in the gut that becomes saturated as the dose increases. Take more gabapentin and, past a certain point, your body simply can’t absorb much more of it. The drug hits a ceiling. Pregabalin, on the other hand, uses additional transport pathways that don’t saturate the same way, giving it linear and predictable absorption. Double the dose and you reliably get roughly double the drug in your bloodstream. That predictability is part of what makes pregabalin more effective as a medication, but it also makes it easier to chase a stronger effect by taking more.
Why Pregabalin Raised Red Flags Before Approval
When Pfizer submitted Lyrica for FDA approval, the clinical trial data showed something the agency doesn’t often see with non-opioid pain medications. Among patients being treated for generalized anxiety disorder, 11.8% of those on the highest dose (450 mg) reported euphoria, compared to just 1.2% on placebo. Even among healthy volunteers in pharmacokinetic studies, nearly 10% experienced euphoria. For a drug intended to treat nerve pain and seizures, those numbers were conspicuous.
The FDA also ran a dedicated abuse-potential study in people with a history of abusing sedatives or alcohol. At doses of 200 and 450 mg, pregabalin produced subjective effects like “good drug effect,” “high,” and “liking” that were similar to or greater than those produced by diazepam (Valium) at 15 and 30 mg. In animal studies, pregabalin was self-administered at rates above placebo, though substantially less than classic sedatives like pentobarbital.
Based on this evidence, the DEA concluded that pregabalin “produces some pharmacological effects characteristic of diazepam and alprazolam and is likely to be abused for its positive psychic effects.” In July 2005, they placed it in Schedule V, the least restrictive controlled substance category, alongside drugs like cough syrups containing small amounts of codeine.
Why Gabapentin Was Not Scheduled
Gabapentin was approved in 1993, a full decade before pregabalin. Its clinical trial data did not show the same pattern of euphoria reports, and its saturable absorption made dose escalation less rewarding. If you take a very high dose of gabapentin hoping for a stronger effect, your gut absorbs a diminishing fraction of each additional pill. The area under the plasma concentration curve doesn’t increase proportionally, which limits the intensity of any subjective “high.”
That doesn’t mean gabapentin has zero abuse potential. It clearly does, and the evidence has mounted over the years. But at the time of its approval, there wasn’t enough signal to trigger scheduling, and the federal government has not revisited that classification. The regulatory system tends to schedule drugs at approval when the data demands it, and retrospective reclassification at the federal level is rare.
States Are Closing the Gap
While gabapentin remains unscheduled under federal law, many states have decided the federal classification doesn’t reflect reality. Between 2016 and 2024, 25 states and territories enacted policies targeting gabapentin. Eight of them, including Kentucky, Tennessee, Virginia, West Virginia, Alabama, North Dakota, Utah, and (briefly) Michigan, classified gabapentin as a Schedule V controlled substance at the state level. Another 17 jurisdictions stopped short of full scheduling but required pharmacies to report gabapentin prescriptions to their prescription drug monitoring programs.
Kentucky was the first to act in 2017. Michigan scheduled gabapentin in 2019 but reversed course and descheduled it in 2024. Utah was the most recent addition, scheduling gabapentin in May 2024. The practical effect in these states is that gabapentin prescriptions face the same tracking and refill restrictions as pregabalin.
The Real-World Harm That Drove State Action
The push to reclassify gabapentin accelerated as data on gabapentinoid-related deaths accumulated. A large Scottish study found that the death rate among people prescribed gabapentinoids was roughly double that of the general population. More troubling, 60% of gabapentinoid patients were simultaneously prescribed an opioid, a benzodiazepine, or both. Those combinations increase the risk of respiratory depression, which is how most drug overdoses become fatal.
Both drugs began showing up in post-mortem toxicology reports at rising rates. In one national analysis, gabapentin was implicated in 23% of drug-related deaths compared to 15% for pregabalin at the regional level, and the gap was similar nationally (15% for gabapentin versus 7% for pregabalin). Researchers noted that much of the harm appeared connected to diversion, meaning people obtained gabapentin from someone else’s prescription or through illicit channels rather than using their own prescriptions as directed.
What This Means for Patients
If you’re prescribed Lyrica, you’ll notice tighter controls at the pharmacy. Refills typically require a new prescription or are limited in number depending on your state, and your prescription will appear in a monitoring database. If you’re prescribed Neurontin, the experience depends on where you live. In states that have scheduled it or added monitoring requirements, your pharmacist will report the prescription the same way they would for pregabalin. In states without such policies, gabapentin is dispensed like any other non-controlled medication.
Neither drug’s scheduling status changes how well it works for the conditions it treats. The classification is purely about abuse risk, not effectiveness. Both remain widely prescribed for nerve pain, certain seizure disorders, and (in pregabalin’s case) generalized anxiety and fibromyalgia. The scheduling distinction reflects a combination of pharmacology, timing, and the specific data that was available when each drug first went through the approval process.